AR034995A1 - SOFT ELASTIC CAPSULE AND METHOD FOR PREPARATION - Google Patents

SOFT ELASTIC CAPSULE AND METHOD FOR PREPARATION

Info

Publication number
AR034995A1
AR034995A1 ARP020101897A ARP020101897A AR034995A1 AR 034995 A1 AR034995 A1 AR 034995A1 AR P020101897 A ARP020101897 A AR P020101897A AR P020101897 A ARP020101897 A AR P020101897A AR 034995 A1 AR034995 A1 AR 034995A1
Authority
AR
Argentina
Prior art keywords
coating
alcohol
agent
soft elastic
initial state
Prior art date
Application number
ARP020101897A
Other languages
Spanish (es)
Inventor
Sergio Petriconi
Roberto Scuppa
A Saleki-Gerhardt
Martin Urch
Alessandro Barbato
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR034995A1 publication Critical patent/AR034995A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cápsula elástica blanda que comprende un relleno y un revestimiento, donde dicho relleno comprende: un agente o combinación de agentes farmacéuticos, un alcohol, un ácido graso, y dicho revestimiento comprende: gelatina, y por lo menos un agente plastificante, donde el antedicho revestimiento tiene un estado inicial y un estado de equilibrio, y en dicho estado inicial se subplastifica el revestimiento y el antedicho relleno contiene una cantidad en exceso de alcohol respecto de la cantidad necesaria para solubilizar el agente farmacéutico y dicho alcohol no está presente en el estado inicial de la composición de revestimiento, y donde en el estado de equilibrio se plastifica el revestimiento mediante el alcohol proveniente del relleno para proporcionar una dureza de la cápsula apropiada y el relleno retiene suficiente alcohol como para mantener al agente farmacéutico en solución. Método para preparar dichas cápsulas. Estas cápsulas elásticas blandas pueden ser utilizadas con un amplio rango de agentes farmacéuticos que incluyen antibioticos, agentes farmacéuticos anti-SIDA, como por ejemplo los compuestos inhibidores de la proteasa de VIH, y toda una serie de otros agentes medicinalmente activos.Soft elastic capsule comprising a filler and a coating, wherein said filler comprises: an agent or combination of pharmaceutical agents, an alcohol, a fatty acid, and said coating comprises: gelatin, and at least one plasticizing agent, wherein said coating it has an initial state and an equilibrium state, and in said initial state the coating is subplastified and the aforementioned filling contains an excess amount of alcohol with respect to the amount necessary to solubilize the pharmaceutical agent and said alcohol is not present in the initial state of the coating composition, and where in the equilibrium state the coating is plasticized by the alcohol from the filling to provide a hardness of the appropriate capsule and the filling retains enough alcohol to keep the pharmaceutical agent in solution. Method for preparing said capsules. These soft elastic capsules can be used with a wide range of pharmaceutical agents including antibiotics, anti-AIDS pharmaceutical agents, such as HIV protease inhibitor compounds, and a host of other medicinally active agents.

ARP020101897A 2001-05-25 2002-05-22 SOFT ELASTIC CAPSULE AND METHOD FOR PREPARATION AR034995A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86628501A 2001-05-25 2001-05-25

Publications (1)

Publication Number Publication Date
AR034995A1 true AR034995A1 (en) 2004-04-14

Family

ID=25347294

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101897A AR034995A1 (en) 2001-05-25 2002-05-22 SOFT ELASTIC CAPSULE AND METHOD FOR PREPARATION

Country Status (8)

Country Link
EP (1) EP1395249A1 (en)
JP (1) JP2005508294A (en)
AR (1) AR034995A1 (en)
CA (1) CA2448438A1 (en)
MX (1) MXPA03010771A (en)
PE (1) PE20030098A1 (en)
UY (1) UY27306A1 (en)
WO (1) WO2002096395A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2871794A1 (en) 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
SI1183026T1 (en) * 1999-06-04 2006-10-31 Abbott Lab Improved pharmaceutical formulations comprising ritonavir
US6608198B2 (en) * 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical

Also Published As

Publication number Publication date
EP1395249A1 (en) 2004-03-10
WO2002096395A1 (en) 2002-12-05
CA2448438A1 (en) 2002-12-05
PE20030098A1 (en) 2003-02-12
MXPA03010771A (en) 2004-07-01
UY27306A1 (en) 2002-12-31
JP2005508294A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
ES2191862T3 (en) LIQUID COMPOSITION INCLUDING AN HIV PROTEASE INHIBITOR AND A FATTY ACID OF C12-C18.
CO5690531A2 (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED
AR024228A1 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULIN SENSITIZER AND ANOTHER ANTI-DIABETIC AGENT
AR022008A1 (en) A COMPOSITION OF CONTROLLED GALANTAMINE RELEASE, A PROCESS FOR THE PREPARATION OF THE SAME, AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR047799A1 (en) SOFT GELATIN CAPSULE CONTAINING A PHARMACEUTICAL FORMULATION WITH AT LEAST ONE OMEGA-3 POLY-INSATURATED FATTY ACID
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
MX9202328A (en) LOCAL PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT.
ES2112547T3 (en) COMPOSITIONS OF WRAPPING OF SOFT GELATIN CAPSULES.
BR0309004A (en) Matrix for gradual, invariant and independent release of active compounds
BR0316310A (en) Pharmaceutical compositions having a modified vehicle
CO2019005729A2 (en) Preparation of solid cyclodextrin complexes for the supply of ophthalmic active pharmaceutical ingredients
BRPI0406905A (en) Clindamycin Phosphate Foam
KR880701544A (en) Dissolution System for Ionizable Pharmaceutical Formulations
UY25055A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE
ES2109493T3 (en) GALLENIC FORM FOR EYE ADMINISTRATION AND PREPARATION PROCEDURE.
AR031547A1 (en) PHYSICAL FORM OF THE SUBSTANCE 5-CHLORINE-N- [2- [4 - [[[(CYCLHEXILAMINO) -CARBONIL] AMINO] SULFONIL] PHENYL] ETHYL] -2-METOXIBENZAMIDE (GLIBURIDE), THE USE OF SUCH SUBSTANCE IN A TABLET OR CAPSULE, TABLETS OR CAPSULES CONTAINING IT AND TABLETS OR CAPSULES CONTAINING IT ASSOCIATED WITH A PHARMACO FOR THE
ES2176785T3 (en) PROCEDURE FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE PRINCIPLE, WHICH INCLUDES A MATRIX.
AR027748A1 (en) SMALL SPHERES OR BALLOONS THAT CONTAIN STAVUDINE AND ALLOW THE CONTROLLED RELEASE OF THE SAME
AR086688A2 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED LIQUID EXCIPIENT, A METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH COMPOSITION TO PREPARE A MEDICINAL PRODUCT
AR034995A1 (en) SOFT ELASTIC CAPSULE AND METHOD FOR PREPARATION
CO5160296A1 (en) NEW FORMS OF PRESENTATION FOR ACTIVE LABOR AGENTS IN THE MIDDLE ACID, ACTIVE AGENT UNIT AND PROCESS FOR THE PRODUCTION OF SUCH AGENT UNIT
AR021921A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS AND BUDESONIDO.
BRPI0418070A (en) personal care composition, use of a substituted urea and method for reducing color degradation of a personal care composition
BRPI0510694A (en) pharmaceutical compositions comprising concentrated soft gelatin encapsulated active ingredients
AR061165A1 (en) FORMULATIONS OF PULSED RELEASE OF PHENYLEFRINE AND PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal